Dendritic cell cancer vaccines: from the bench to the bedside.
about
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of ImmunotherapyRestoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and PreventionImmune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.
P2860
Dendritic cell cancer vaccines: from the bench to the bedside.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Dendritic cell cancer vaccines: from the bench to the bedside.
@en
Dendritic cell cancer vaccines: from the bench to the bedside.
@nl
type
label
Dendritic cell cancer vaccines: from the bench to the bedside.
@en
Dendritic cell cancer vaccines: from the bench to the bedside.
@nl
prefLabel
Dendritic cell cancer vaccines: from the bench to the bedside.
@en
Dendritic cell cancer vaccines: from the bench to the bedside.
@nl
P2093
P2860
P356
P1476
Dendritic cell cancer vaccines: from the bench to the bedside.
@en
P2093
David Avigan
Irit Avivi
Jacalyn Rosenblatt
Noam Benyamini
Tamar Katz
P2860
P356
10.5041/RMMJ.10158
P407
P577
2014-10-29T00:00:00Z